# Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

> **NCT01932242** · PHASE1 · COMPLETED · sponsor: **Elusys Therapeutics** · enrollment: 70 (actual)

## Conditions studied

- Inhalational Anthrax

## Interventions

- **BIOLOGICAL:** ETI-204
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01932242
- **Lead sponsor:** Elusys Therapeutics
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-23
- **Primary completion:** 2014-04-19
- **Final completion:** 2014-04-19
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2019-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01932242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01932242, "Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01932242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*